Quick Answer
Immunocore Holdings plc reported Total Revenue of $400.02 million for fiscal year 2025.
Immunocore Holdings plc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $400.02M +29.0% |
$310.20M +24.4% |
$249.43M +43.1% |
$174.36M +377.9% |
$36.48M | — |
| Revenue (ASC 606) | $400.02M +29.0% |
$310.20M +24.4% |
$249.43M +43.1% |
$174.36M +4175.6% |
$4.08M | — |
| Net Income | -$35.51M +30.5% |
-$51.09M +7.6% |
-$55.29M -5.2% |
-$52.54M +70.8% |
-$180.03M | — |
| Diluted EPS | -$0.71 +30.4% |
-$1.02 +9.7% |
-$1.13 +1.7% |
-$1.15 +72.9% |
-$4.24 | — |
| Total Assets | $1.07B +5.7% |
$1.01B +69.1% |
$597.00M +13.3% |
$526.76M +74.6% |
$301.77M +53.0% |
$197.19M +6.2% |
| Cash and Equivalents | $467.71M +2.6% |
$455.73M +3.0% |
$442.63M +10.0% |
$402.47M | — | — |
| Stockholders Equity | $381.03M +5.6% |
$360.72M -2.2% |
$368.84M +8.8% |
$338.90M +45.0% |
$233.71M +203.9% |
$76.91M |
| R&D Expense | $274.87M +23.7% |
$222.15M +35.8% |
$163.54M +60.5% |
$101.92M +1.7% |
$100.25M +34.0% |
$74.81M -25.2% |
| Operating Income | -$45.35M +35.6% |
-$70.46M -18.1% |
-$59.65M -15.4% |
-$51.71M +70.4% |
-$174.59M | — |
| Shares Outstanding | 50.69M +1.2% |
50.06M +0.7% |
49.73M +3.4% |
48.09M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $103.69M | +29.2% | +5.8% |
| Revenue (ASC 606) | September 30, 2025 | $103.69M | +29.2% | +5.8% |
| Net Income | September 30, 2025 | -$177.0K | -102.0% | +98.3% |
| Diluted EPS | September 30, 2025 | $0.00 | -100.0% | +100.0% |
| Total Assets | September 30, 2025 | $1.10B | +1.6% | +1.9% |
| Cash and Equivalents | September 30, 2025 | $498.41M | -7.3% | +2.1% |
| Stockholders Equity | September 30, 2025 | $396.56M | +5.0% | +2.1% |
| R&D Expense | September 30, 2025 | $70.57M | +33.7% | +2.3% |
| Operating Income | September 30, 2025 | -$7.17M | +15.7% | +51.8% |
| Shares Outstanding | September 30, 2025 | 50.47M | +0.9% | +0.2% |
- Immunocore Holdings plc reported Total Revenue of $400.02 million for fiscal year 2025.
- Immunocore Holdings plc showed an increase of +29.0% in Total Revenue compared to the prior fiscal year.
- Immunocore Holdings plc reported Revenue (ASC 606) of $400.02 million for fiscal year 2025.
- Immunocore Holdings plc showed an increase of +29.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Immunocore Holdings plc reported Net Income of -$35.51 million for fiscal year 2025.
- Immunocore Holdings plc showed an increase of +30.5% in Net Income compared to the prior fiscal year.
- Immunocore Holdings plc reported Diluted EPS of $0.71 per share (loss) for fiscal year 2025.
- Immunocore Holdings plc showed an increase of +30.4% in Diluted EPS compared to the prior fiscal year.
- Immunocore Holdings plc reported Total Assets of $1.07 billion for fiscal year 2025.
- Immunocore Holdings plc showed an increase of +5.7% in Total Assets compared to the prior fiscal year.
- Immunocore Holdings plc reported Cash and Equivalents of $467.71 million for fiscal year 2025.
- Immunocore Holdings plc showed an increase of +2.6% in Cash and Equivalents compared to the prior fiscal year.
- Immunocore Holdings plc reported Stockholders Equity of $381.03 million for fiscal year 2025.
- Immunocore Holdings plc showed an increase of +5.6% in Stockholders Equity compared to the prior fiscal year.
- Immunocore Holdings plc reported R&D Expense of $274.87 million for fiscal year 2025.
- Immunocore Holdings plc showed an increase of +23.7% in R&D Expense compared to the prior fiscal year.
- Immunocore Holdings plc reported Operating Income of -$45.35 million for fiscal year 2025.
- Immunocore Holdings plc showed an increase of +35.6% in Operating Income compared to the prior fiscal year.
- Immunocore Holdings plc reported Shares Outstanding of 50.69 million shares for fiscal year 2025.
- Immunocore Holdings plc showed an increase of +1.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: